Edition:
India

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

15.90USD
2:29am IST
Change (% chg)

$-0.09 (-0.56%)
Prev Close
$15.99
Open
$15.98
Day's High
$16.57
Day's Low
$15.75
Volume
500,143
Avg. Vol
387,370
52-wk High
$19.94
52-wk Low
$13.44

Chart for

About

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $2,604.40
Shares Outstanding(Mil.): 149.59
Dividend: --
Yield (%): --

Financials

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

16 Jan 2018

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017

08 Jan 2018

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

04 Dec 2017

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

28 Nov 2017

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​ Source text: (http://bit.ly/2h08KF7) Further company coverage:

03 Nov 2017

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

06 Sep 2017

FDA approves Ironwood Pharma's gout drug

Aug 21 Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.

21 Aug 2017

BRIEF-Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout

* Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout

21 Aug 2017

BRIEF-Ironwood Pharmaceuticals Q2 loss per share $0.30

* Ironwood Pharmaceuticals provides second quarter 2017 investor update

04 Aug 2017

Earnings vs. Estimates